SRM-2015-02_E
(DCO 3277)Confidential Page [ADDRESS_638740]-APPROVAL STUDY of TRANSCAROTID ARTERY 
REVASCULARIZATION in PATIENTS with SIGNIFICANT CAROTID 
ARTERY DISEASE. 
 The ROADSTER 2 Study 
Clinical Protocol SRM â€“2015 â€“02
Version E
Version Date February 10, 2017
Sponsored by: 
[CONTACT_496827], Inc. 
[ADDRESS_638741] 
Sunnyvale, CA  [ZIP_CODE] 
[LOCATION_002] of America 
Phone: +[PHONE_10324] 
Fax: +[PHONE_10325] 1&7
  
SRM -2015 -02_E  
(DCO 3277 ) Confidential  Page [ADDRESS_638742] -APPROVAL STUDY  of TRANSCAROTID ARTERY 
REVASCULARIZATION in PATIENTS with  SIGNIFICANT CAROTID 
ARTERY DISEASE. (The ROADSTER 2 Study ) 
Objective  
 The ROADSTER [ADDRESS_638743] 600 patients.  A physician  may enroll 
more than 30 patients .   
Investigation Site  
Locations  A minimum of 30 and up to a maximum of  100 sites in the [LOCATION_002] . A 
maximum of 5 sites in the European Union.  No more than 30% of the sites 
will be sites that previously enrolled in the ROADSTER study.  
Primary Endpoint  The rate of procedural success through 30 days following stent implant . 
Secondary 
Endpoints  The following secondary endpoints will be assessed 0 to 30 days:  
ï‚§ Acute device success  
ï‚§ Technical success  
ï‚§ Rate of cranial nerve injury  
ï‚§ Rate of c ardiac  death  
ï‚§ Rate of neurological death  
ï‚§ Rate of hierarchical ipsilateral stroke , death  and MI  
ï‚§ Rate of hierarchical ipsilateral stroke, death  and MI  by [CONTACT_496828]  
ï‚§ Acute device, technical and procedural success  by [CONTACT_496829]  
ï‚§ Acute device, technical and procedural success by [CONTACT_496830] g 
level 
ï‚§ Acute device, technical and procedural  success by [CONTACT_496831] (ICA) with 
or without involvement of the contiguous common artery (CCA) determined 
by [CONTACT_136665] , CT/CTA, MR/MRA  or angiography  to be:  Symptomatic 
(ï‚³ 50% stenosis ) or Asymptomatic (ï‚³ 80% stenosis ) 
Planned Schedule  Commence Enrollment : Q3 2015  
Complete Enrollment:  End of Q1 2018  
Complete 30 -day Follow -Up:    [ADDRESS_638744] enrollment  
Issue FDA Final Report:           Beginning of Q3 2018  
 
   
SRM -2015 -02_E  
(DCO 3277 ) Confidential  Page 23 of 46 
 
 Adjudication of Events  
 Clinical Events Committee (CEC)  
An independent Clinic al Events Committee will be assembled to review and adjudicate strokes, 
cranial nerve injuries, and UADEs (and their relationship to the device or procedure) events , as 
well as major protocol deviations  affecting patient safety , that occur while a patient is enrolled in 
the study .  The committee will be comprised of a multidisciplinary group of physicians including at 
least one neurologist , at least one vascular surgeon  and at least one cardiologist. The committee 
members will not be participating in the tr ial and will not have an affiliation with the Sponsor, 
Investigators, or Study  sites.  
 Strokes  
The CEC will adjudicate all suspected strokes.   
15.2.1  Major Stroke  
A Major Stroke  is to be defined as an increase of 5 or more in NIH Stroke Scale from baseline 
score and a Modified Rankin Score of â‰¥3. 
 
Note:  If NIH â‰¥4 at enrollment, any change â‰¥5 is considered a major stroke.  If Rankin â‰¥3 at 
enrollment, and change â‰¥[ADDRESS_638745] 2.  
 
Note:  If NIH â‰¥4 at enrollment, any change â‰¤4 is considered a minor stroke  
 
 Cranial Nerve Injuries  
The CEC will adjudicate all  suspected cranial nerve injuries that occur  within 30 days  (+7 days)  of 
the procedure.  
 Statistical Methods and Determination of Sample Size   
 Overview  
The following section provides an outline of the statistical methods to be applied to the clinical 
data from this study .  A Statistical Analysis Plan, containing the details for generating the 
analyses, will be finalized prior to any analyses being conduct ed. 
16.1.1  Sample Size Calculation  
The sample size for this clinical investigation is based on the rate of procedural success within 30 
days of the stent implant.  The observed rate of procedural success in the ROADSTER 2 Study  
will be compared to an a priori  threshold of 85% derived from the ROADSTER Study.  The 
   
SRM -2015 -02_E  
(DCO 3277 ) Confidential  Page 24 of 46 
 rationale for an 85% threshold is based on the lower bound of the 2 -sided 95% exact binomial 
confidence intervals of the procedural success rates from the ROADSTER Lead -In Phase 
(91.0%, 95% CI 81.52%,  96.64%) and the ROADSTER Pi[INVESTIGATOR_9205] (95.7%, 95% CI 90.97%, 
98.42%).  Given that the majority of sites that will participate in the ROADSTER [ADDRESS_638746] consider outcomes 
from early enrollment.  With an observed rate of procedural success >89% in the ROADSTER 2 
Study , the results will be significant with a minimum of 600 patients, meaning the lower bound of 
the 2 -sided 95% exact binomial confidence interval will exceed 85%.  Det erministically, if 534 
patients of the 600 total cases (89%) were classified as a procedural success within [ADDRESS_638747] 95% lower binomial confidence limit would be 86.22%.  
Estimates for the 3 categories of physician level of training and experience (yes/no) will be 
summarized.  However, given the distribution of physicians by [CONTACT_496832], it is indeterminate how informative the estimates 
will be. 
 Endpoint Analyses and Hypothesis Testing  
The hypothesis testing will be focused on the proportion of patients classified as a procedural 
success, and to examine differences among the levels of physician training and the experience  of 
physicians .  
16.2.[ADDRESS_638748] observation will be 
count ed in the analysis as a procedural success.  Secondary analyses of the primary endpoint 
will consider alternative methods of imputation; the details of these supplemental analyses will be 
described in the Statistical Analysis Plan.    
16.2.[ADDRESS_638749], compared to an a priori  threshold of 
85.0%.  The 2 -sided 95% exact binomial confidence intervals will also be presented.  Patients 
who withdraw prio r to [ADDRESS_638750] -procedure; each of the secondary endpoints is a 
dichotomous variable:  
ï‚· Acute device success  
ï‚· Technical succ ess 
ï‚· Rate of cranial nerve injury  
   
SRM -2015 -02_E  
(DCO 3277 ) Confidential  Page 25 of 46 
 ï‚· Rate of cardiac  death  
ï‚· Rate of neurological death  
ï‚· Rate of hierarchical ipsilateral stroke, death and MI  
ï‚· Rate of hierarchical ipsilateral stroke, death and MI by [CONTACT_496828]  
ï‚· Acute device, technical and procedural success by [CONTACT_496833]  
ï‚· Acute device, technical and procedural success by [CONTACT_496834]  
ï‚· Acute device, technical and procedural success by [CONTACT_496835] -procedure observations will serve as the baseline  values fo r calculating post procedure 
changes from baseline.  Tabulations of summary statistics, graphical presentations, and statistical 
analyses will be performed using SAS software version 9.2 or higher.  The statistical analyses will 
be based on data pooled acr oss Sites  in aggregate ; a secondary tabulation will be prepared 
separately for the US and Non -US sites .  Continuous demographic parameters, such as the age 
of the patient at the time of enrollment, will be summarized for the Per -Protocol population using 
descriptive statistics (N, mean, median, standard deviation, minimum and maximum value, and 
95% 2 -sided confidence limits).  Continuous demographic parameters will be compared among 
the 3 levels of physician training and experience using a 1 -factor (physici an training  [1, 2 or 3] ; 
physician experience [participation in ROADSTER 1 or no participation in ROADSTER 1 ) analysis 
of variance model.  Contrast statements will be used to evaluate the individual pair wise 
comparisons (Level 1 vs. Level 2, Level 1 vs. L evel 3, and Level 2 vs. Level 3 ; participation in 
ROADSTER 1 vs no participation in ROADSTER 1 ).  Categorical demographic parameters, such 
as gender, will be summarized as a proportion of the Per -Protocol population using Clopper -
Pearson 95% [ADDRESS_638751] stratified on physician level of training (1, 2, or 3) and 
separately by [CONTACT_496833]  (participation in ROADSTER 1 vs no participation in 
ROADSTER 1) .  Additionally, a generalized linear model (PROC GENMOD) will be used to 
evaluate the main effect of physician level of experience, specifying the distribution as either 
binomial or multinomial.  Clinical and high risk factors will also be summarized as a  proportion of 
the Per -Protocol population with Clopper -Pearson 95% 2 -sided confidence limits.  In addition to 
the overall summary of the individual factors, separate summaries will be generated by [CONTACT_496836] .  Comparisons w ill be made among the 3 levels of physician 
training and physician experience  (participation in ROADSTER 1 vs no participation in 
ROADSTER 1) , depending on the type and distribution of the parameter.  
 
Data obtained during the neurological examination, including data from the NIH Stroke Scale, 
Modified Rankin Scale and Cranial Nerve Palsy Assessment will be summarized at each time 
point using descriptive statistics.  Separate summaries will be generated by [CONTACT_496837] a 1 -factor (physician level of training  [1, 2 or 3] ) and 
a 1-factor (experience: participation in ROADSTER 1 vs. no participation in ROADSTER 1 ) 
analysis of variance model.  Contrast statements will be used to evaluate the individual pair wise 
comparisons (Level 1 vs. Level 2, Level 1 vs. Level 3, and Level 2 vs. Level 3).    
 
Specific algorithms for imputing missing or partially missing dates wi ll be discussed in the SAP.  
Derived data will be identified in the individual patient data listings.  Imputed data for dates will not 
   
SRM -2015 -02_E  
(DCO 3277 ) Confidential  Page [ADDRESS_638752] not meeting the Inclusion/ Exclusion criteria will be tabulated but not 
included in the primary endpoint analysis.  
 
 Data Collection  
Data will be entered into a validated electronic data management system.  Data fields in the 
selected electronic data management system used will be aligned such that it overlaps with the 
appropriate data fields for the post -approval study as derived from the ROADSTER IDE.  
 Sponsor Responsibilities  
 Selection of Clinical Investigators and Sites  
All US sites p articipat ing in the ROADSTER 2 Study  will be l imited to institutions with current 
CMS carotid stent certification.  Institutions will be compensated for complete and accurate data 
collection.  
 Training of Investigators and Site Personnel  
Investigators and site personnel will be trained on the followin g aspects of the clinical study:  
ï‚Ÿ Protocol  
ï‚Ÿ Case Report Forms  
ï‚Ÿ Risks and Benefits  
ï‚Ÿ Reporting Responsibilities  
ï‚Ÿ Informed Consent  
ï‚Ÿ Device Usage  
ï‚Ÿ Device Instructions for Use  
ï‚Ÿ Confidentiality  
Investigator responsibilities are further detailed below.  